This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the odds ratio (OR) for continued cessation after one year, as compared with no intervention; the proportion of smokers who stop treatment after the first or second month; the lifetime probability of relapse after one year of abstinence; the probability of current smokers being truly prepared to make a serious quit attempt; and the mortality effects of smoking cessation.
Study designs and other criteria for inclusion in the review
It was not stated whether a systematic review of the literature was undertaken to identify primary studies. The design of the sources used was not provided. Some data were not available for the Seychelles, so data obtained from other countries were used instead.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Fourteen primary studies provided the data.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The natural cessation rate among smokers was 2.5% (range: 1 -4).
The OR for continued cessation after one year was:
1.73 (range: 1.46 -2.03) with counselling alone, compared with no intervention;
1.66 (range: 1.52 -1.82) with nicotine gum, compared with counselling alone;
1.80 (range: 1.61 -2.01) with nicotine patch, compared with counselling alone; 2.35 (range: 1.63 -3.38) with nicotine spray, compared with counselling alone; 2.14 (range: 1.44 -3.18) with nicotine inhaler, compared with counselling alone; and 2.51 (range: 1.5 -2) with bupropion, compared with counselling alone.
The rate of smokers who stop treatment was 50% (range: 40 -60) after the first month and 20% (range: 15 -25) after the second month.
The lifetime probability of relapse after one year of abstinence was 35% (range: 10 -50). The probability of current smokers being truly prepared to make a serious quit attempt was 25%.
The excess mortality risk declined significantly within the first years after cessation. The mortality rate of a former smoker finally rejoined that of never smokers approximately 20 years after quitting.
Measure of benefits used in the economic analysis
The summary benefit measure used was the life-years saved (LYS) with each pharmacological smoking cessation therapy in comparison with counselling alone. The LYS were derived using a modelling approach and an annual discount rate of 3% was applied.
Direct costs
Discounting was not relevant because of the short time horizon considered (treatment was assumed to last 3 months). The unit costs were presented separately from the quantities of resources used for most items. The health services included in the economic evaluation were pharmacological smoking cessation therapies and physician time for counselling and treatment. The cost/resource boundary of the third-party payer was adopted. Resource use was estimated mainly on the basis of authors' assumptions. The costs were derived from US retail prices for pharmacological smoking cessation therapies and from average monthly wages for providers' time (including allowances and benefits). The costs were estimated in 2002 and 2003, but the price year was not explicitly reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency
The costs were estimated in Seychelles rupees, and then converted into US dollars ($). The conversion rate was Seychelles rupees 5 = $1.
Sensitivity analysis
A multivariate sensitivity analysis was performed. This not only examined the influence of some model inputs (e.g. discount rate, treatment costs, and provider salaries), but also extended the relevance of the results to other developing countries. The sensitivity analysis was carried out on a hypothetical 45-year-old male smoker. The alternative discount rates were 0, 5 and 10%. Treatment price lists were considered as low as 12.5% of the base-case (US) prices. Lower physician salaries were also considered.
Estimated benefits used in the economic analysis
The estimated LYS with each smoking cessation therapy were not reported.
Cost results
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The total and incremental costs of each smoking therapy were not reported.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios (ICERs), namely the incremental cost per LYS, were calculated to combine the costs and benefits of the smoking cessation therapies in comparison with counselling alone.
In men (women), the ICER for nicotine gum was $4,385 ($7,894) in the age class 20 -34 years, $3,675 ($5,753) in the age class 35 -49 years, and $4,870 ($6,097) in the age class 50 -64 years.
In men (women), the ICER for nicotine patch was $2,341 ($4,214) in the age class 20 -34 years, $1,962 ($3,071) in the age class 35 -49 years, and $2,600 ($3,255) in the age class 50 -64 years.
In men (women), the ICER for nicotine spray was $5,430 ($9,777) in the age class 20 -34 years, $4,551 ($7,124) in the age class 35 -49 years, and $6,032 ($7,551) in the age class 50 -64 years.
In men (women), the ICER for nicotine inhaler was $5,069 ($9,125) in the age class 20 -34 years, $4,248 ($6,650) in the age class 35 -49 years, and $5,630 ($7,048) in the age class 50 -64 years.
In men (women), the ICER for bupropion was $1,564 ($2,817) in the age class 20 -34 years, $1,311 ($2,052) in the age class 35 -49 years, and $1,738 ($2,175) in the age class 50 -64 years.
Therefore, the pharmacological smoking cessation therapies were more effective in men than in women, and bupropion was the most cost-effective option. The ICER was lowest for men and women in the age class 35 -49 years.
The multivariate sensitivity analysis showed that treatment price and discount rate had the greatest impact on the results. For example, assuming the wages of a Seychelles general practitioner (GP) and a 3% discount rate, the cost per LYS with nicotine gum was over six times higher at 100% US treatment prices than at 12.5% treatment prices ($3,712 versus $599).
Based on these same assumptions, the cost per LYS for bupropion was 8.6 times higher at 100% versus 12.5% US prices ($1,952 versus $227) . Assuming the wages of a Seychelles GP and 50% treatment prices, the cost per LYS with the nicotine patch was 11.4 times higher when applying a 10% discount rate than when applying a 0% discount rate ($5,219 versus $458).
Authors' conclusions
Pharmacological smoking cessation therapies, particularly bupropion, nicotine patch and nicotine gum, were costeffective in comparison with physician counselling alone in the Seychelles. However, the authors stressed that affordability represents a key issue in developing countries.
CRD COMMENTARY -Selection of comparators
The selection of the comparators was appropriate because physician counselling represented the standard approach for enhancing smoking cessation. The five interventions under evaluation represent commonly used pharmacological smoking cessation therapies. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence came from published studies. However, it was unclear whether a systematic review of the literature was undertaken. In fact, it appears that the primary studies have been identified selectively. No information on the design of the primary sources was provided, and some data came from studies that did not reflect the Seychelles setting. Therefore, it is not possible to assess the validity of the primary studies. The methods used to extract and then combine the primary estimates were not explicitly reported. In some cases, conservative assumptions were made. The issue of uncertainty in the clinical data was not explicitly addressed in the sensitivity analysis, but the authors stated that the wide OR associated with some treatments (e.g. nicotine spray and inhaler) could result in changes in the ICER.
